Wall Street analysts pointed out that Merck & Co IncThe company's clinical data and scale production capacity of the anti-novel coronavirus drug will change the pattern of the pandemic, and the drug may be authorized for emergency use this year.
Merck & Co Inc's share price soared as much as 12 per cent after the data was released; Atea, which is working with Roche to develop anti-novel coronavirus drugs, rose 33 per cent after Merck & Co Inc's data were released.
Umer Raffat, an analyst at Evercore ISI, said the drug would "change the rules of the game" for COVID-19 's epidemic, writing that its clinical data were "really good".
Oral medicine is expected to make "significant progress" in the fight against COVID-19, which will change the epidemic pattern because of its ease of use and large-scale production capacity.
Barclays analyst Carter Gould expects the drug to be directly licensed for emergency use by FDA.
Louise Chen, an analyst at Cantor, stressed that the data showed that the drug had the same effect on Gamma, Delta and Mu variants, and said the drug could "change COVID-19 's treatment model."
Daina Graybosch, an analyst at SVB Leerink, wrote that the drug could receive orders of more than $10 billion in the short term and "represents the best option for global control of the epidemic."
Approval from the United States is expected by the end of the year, and there will be more supply contracts in the coming weeks.
Morgan StanleyMatthew Harrison wrote that the data is a significant boon to the broader public perception of risk associated with COVID-19.